Analysts Set Trevena, Inc. (TRVN) Target Price at $9.32

Trevena, Inc. (NASDAQ:TRVN) has received a consensus rating of “Buy” from the twelve brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $8.65.

A number of equities research analysts have recently issued reports on TRVN shares. Zacks Investment Research upgraded Trevena from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a report on Wednesday, October 18th. Needham & Company LLC reduced their price objective on Trevena from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. HC Wainwright reduced their price objective on Trevena from $8.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, October 12th. Barclays cut Trevena from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $15.00 to $2.50 in a report on Monday, October 16th. Finally, Oppenheimer set a $5.00 price objective on Trevena and gave the stock a “buy” rating in a report on Thursday, October 12th.

Hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in Trevena by 528.5% during the second quarter. Dimensional Fund Advisors LP now owns 711,615 shares of the biopharmaceutical company’s stock valued at $1,637,000 after purchasing an additional 598,383 shares in the last quarter. Vanguard Group Inc. raised its position in Trevena by 15.0% during the second quarter. Vanguard Group Inc. now owns 1,822,103 shares of the biopharmaceutical company’s stock valued at $4,191,000 after purchasing an additional 238,089 shares in the last quarter. Northern Trust Corp raised its position in Trevena by 15.8% during the second quarter. Northern Trust Corp now owns 572,662 shares of the biopharmaceutical company’s stock valued at $1,318,000 after purchasing an additional 77,934 shares in the last quarter. Northpointe Capital LLC raised its position in Trevena by 5.0% during the third quarter. Northpointe Capital LLC now owns 1,283,025 shares of the biopharmaceutical company’s stock valued at $3,272,000 after purchasing an additional 61,546 shares in the last quarter. Finally, State Street Corp raised its position in Trevena by 8.3% during the second quarter. State Street Corp now owns 768,249 shares of the biopharmaceutical company’s stock valued at $1,767,000 after purchasing an additional 58,895 shares in the last quarter. Institutional investors and hedge funds own 56.27% of the company’s stock.

Shares of Trevena (NASDAQ:TRVN) traded down $0.01 during trading hours on Thursday, hitting $1.65. The stock had a trading volume of 559,904 shares, compared to its average volume of 755,129. Trevena has a 12 month low of $1.35 and a 12 month high of $8.00. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.92 and a quick ratio of 4.92.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.06. During the same period in the prior year, the firm posted ($0.57) EPS. sell-side analysts predict that Trevena will post -1.25 earnings per share for the current fiscal year.

WARNING: “Analysts Set Trevena, Inc. (TRVN) Target Price at $9.32” was posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.com-unik.info/2017/12/03/analysts-set-trevena-inc-trvn-target-price-at-9-32.html.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

What are top analysts saying about Trevena Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Trevena Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit